Endothelial dysfunction underlie thrombotic microangiopathies and malignant hypertension.
Endothelial dysfunction likely promotes hypertension and microangiopathic hemolytic anemia.
Alternative complement activation may also be important in malignant hypertension and TMA.
Reducing endothelial injury via complement inhibition beneficial in atypical HUS.
Clinical trials needed to test targeting endothelium in TTP and malignant hypertension.